[Treatment of patients with destructive arthritis with certolizumab pegol]. / Therapie mit Certolizumab pegol bei Patienten mit destruierender Arthritis.
Z Rheumatol
; 69(7): 653-6, 2010 Sep.
Article
em De
| MEDLINE
| ID: mdl-20532790
ABSTRACT
Certolizumab pegol is a new anti-TNF-alpha inhibitor which has been approved for the treatment of rheumatoid arthritis since October 2009. Due to the modification of the antibody fragment by the adherence of polyethylene glycol (PEG) a sufficient distribution in inflammatory tissue was found in animal experiments. In two individual case reports a remission of therapy refractive arthritis was achieved by administration of certolizumab pegol.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Polietilenoglicóis
/
Artrite Reumatoide
/
Fragmentos Fab das Imunoglobulinas
Idioma:
De
Ano de publicação:
2010
Tipo de documento:
Article